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Higher DNA methylation of ABO gene promoter is
associated with acute myocardial infarction in a
hospital-based population in Karachi
Farzana Abubakar Yousuf1, Khawar Kazmi2, Junaid Iqbal3,
Nikhat Ahmed4, Mohammad Perwaiz Iqbal5
ABSTRACT
Objective: To find out if there is any relationship of methylation status of ABO gene promoter with
the risk of acute myocardial infarction (AMI) in a hospital-based Pakistani population in Karachi,
Pakistan.
Methods: A case control study comprising of 39 adult AMI patients (both males and females; age range
30-70 years) and 39 normal healthy controls (both males and females and similar age range) nested in a
large study (to see the relationship of ABO genotypes with AMI) was designed to investigate the methylation
status of ABO gene promoter and its association with AMI. The study was carried out at the Aga Khan
University, Karachi during July 2018 to June 2019. DNA isolated from samples of AMI patients and normal
healthy controls were converted into bisulphite DNA using a kit method. Methylation specific polymerase
chain reaction was carried out to determine the methylation status of ABO gene promoter in both cases and
controls. Logistic regression was used to find out any association between increased methylation status of
ABO gene promoter and risk of AMI.
Results: A significantly higher percentage of DNA methylation of the ABO gene promoter was observed
in AMI patients as compared to normal healthy controls (82.1% vs. 35.9%; p value <0.001). This higher
methylation status of ABO gene promoter was associated with AMI and the odds of AMI in this population
were more than 6-fold in subjects with methylated gene promoter compared to those with unmethylated
gene promoter after adjusting with age and waist circumference [AOR (95% CI) = 6.27 (1.76-22.3); p value
= 0.005].
Conclusion: The ABO gene promoter’s hypermethylation appears to be increasing the risk of AMI in a
hospital-based Pakistani population in Karachi, Pakistan.
KEYWORDS: ABO gene promoter, Acute myocardial infarction, Coronary artery disease, DNA methylation,
Pakistani population.
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ABO gene locus encodes for glycosyl
transferases which modify the terminal
oligosaccharides of the precursor H antigen,
thereby making antigen A and antigen B. While
A and B alleles of ABO gene are enzymatically
active, the O allele is inactive, and therefore
cannot modify precursor H antigen leading to
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O antigen. 1 Therefore, expression of ABO gene
locus is associated with the expression of ABO
phenotypes in individuals.
A systematic review by Chen et al., 2016 has
shown an association of blood group A and non
O blood groups with increased risk of coronary
artery disease (CAD).2 A recent report from China
indicated that blood group A was an independent
risk factor for severity of CAD.3 These reports
show that expression of ABO gene has an indirect
relationship with the development of CAD.
DNA methylation is an epigenetic modulation
mechanism in which cytosine bases of the
eukaryotic DNA immediately followed by
guanine residues i.e. CpG (cytosine-phosphateguanine) islands present in the promoter region
are converted to 5 methylcytosine with the
help of the enzyme DNA methyltransferases.4
ABO gene promoter region has a CpG island
whose methylation status correlated with gene
expression in the cell lines.5 A study by Zaina et al.
showed an association of differentially methylated
CpG islands with the onset of atherosclerosis
and endothelial dysfunction.6 Since ABO gene
locus has also been identified to be associated
with myocardial infarction in patients with CAD
symptoms,7 it is imperative to investigate the
methylation status of ABO gene promoter to see
whether it has a relationship with acute myocardial
infarction (AMI) in a Pakistani population which
has one of the highest known rates of CAD in the
world.8 While a few studies have been carried
out to study the effect of epigenetic factors on
some of the clinical diseases such as metabolic
diseases and psychiatric illnesses among South
Asian immigrants in the West, hardly any
investigation on the role of DNA methylation
and the development of premature CAD has
been conducted on South Asians.9,10 Therefore the
objective of the study was to find out if there is any
relationship of methylation status of ABO gene
promoter with the risk of AMI in a hospital-based
Pakistani population.
METHODS
Study design, sampling and sample size: This
is a case control study nested in a large cohort
study which had the purpose to investigate the
relationship of ABO genotypes with AMI in a
Pakistani population in Karachi. For the large
study, the AMI patients’ samples (both males
and females with the age range from 30-70 years
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and having a confirmed diagnosis of AMI) had
been obtained from the National Institute of
Cardiovascular Disease (NICVD), Karachi with
informed consent, while normal healthy subjects
(both males and females with same age range from
30-70 years and not suffering from any chronic
disease including CAD) were recruited from the
personnel of the Aga Khan University (AKU)
and NICVD. The study had the approval of the
Ethics Review Committees (ERC) (Ref#: 3048-BBSERC-14 dated on July 17, 2018) of the AKU and
NICVD (Ref#: ERC-10/2015 dated on May 30,
2015). The nested current case control study was
carried out at the AKU during the period July
2018 to June 2019. DNA samples isolated from
AMI patients (n=39) and normal healthy controls
(n=39) were randomly selected from the samples
collected for the large study.
Sample Size: In a case control design with power
of at least 80% and level of significance of 5%, a
sample size of 39 in each patients group (cases)
and healthy subjects group (control) was worked
out when exposure ranged from 10% - 45% with an
anticipated odds ratio of four or more.11 Therefore,
39 DNA samples of AMI patients and 39 DNA
samples of healthy controls were employed for
methylation profiling of ABO gene promoter to
investigate any association of methylation status
of promoter and risk of AMI in this population.
Demographic and clinical characteristics of patients
and healthy controls such as gender, age, body
mass index (BMI), waist circumference (WC) and
blood pressure were obtained from the record of
the study participants.
DNA Extraction and Bisulfite Conversion: Salting
out method was used for isolation of genomic
DNA from white blood cells of AMI patients and
normal healthy control subjects using standard
protocol.12 The amount of DNA was quantitated
at 260 nm and the purity was checked by taking
the optical density (OD) at the ratio 260/280. The
DNA methylation experiments were then carried
out on the purified DNA.
The MethylEasy™ Xceed Rapid DNA Bisulphite
Modification Kit (Genetic signatures company,
Australia) was used for the conversion of DNA
into bisulphite DNA following manufacturer’s
instruction. In this process, cytosine is converted
to uracil but does not convert 5-methylcytosine
(5-mc) bases as they are unreactive. The genomic
DNA (5 µg) obtained from both the study groups
(cases and controls) along with a positive control
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1 (untreated DNA, as provided in the kit) was
used. The integrity of the DNA samples after
bisulphite conversion was checked by nested
PCR using primers 3A (first round) and 3B
(second round) and a control sample 2 (which
contained bisulphite treated DNA) as positive
control (all provided in the kit). The product size
of the amplicon was 240bp that was analyzed on
a 2% agarose gel. Now the bisulfite treated DNA
samples were ready to be used in methylation
specific PCR (MSP) for the profiling of ABO
gene promoter.
Methylation specific PCR (MSP): The MSP
technique detects the average DNA methylation
status of any gene. The targeted methylated region
of the human ABO gene was amplified by using
methylation specific primers and unmethylated
specific primers as described by Kominato
et al.5 The unmethylated primer sequences
for forward and reverse primers were (U1)
5’GGATAGGGTTTTAAGGTATTAGGGTTATG3’
and (U2) 5’CCACATCTAATCTCAACCTCCA3’,
respectively. The steps for the amplifications
of unmethylated PCR reaction were: initial
denaturation for nine minutes at 95°C (one
cycle only), then 38 repeated cycles of one
minute at 94°C, one minute at 60°C, two minute
at 72°C and extension at 72°C for 10 minutes.
The methylation specific primer sequences
of forward and reverse primers were M1
5’TTAAGGTATTAGGGTTACGAGGGGC3’
and
M2
5’CGACCATAACTCCGCGTCT3’,
respectively. The amplification of the methylated
PCR reaction was performed as described in the
following: Initial denaturation at 95°C for 9 minutes
(one cycle only) and then 38 repeated cycles at 94°C
for one minute, 67°C 1 minute, 72°C two minutes
and extension at 72°C for 10 minutes. The total
reaction volume was 50 µl containing two units of
AmpliTaq Gold® 360 DNA polymerase (Applied
Biosystems®) and 20 ng of bisulfite converted
DNA. The 2% agarose gel containing ethidium
bromide was used to visualize the amplified PCR
products which had a size of 280bp.
Statistical Analysis: Demographic and clinical
data were analyzed using Statistical Package for
Social Sciences (SPSS) software version 19 for
Windows (Apache Software Foundation, USA)
by IBM. The mean ± SD values of continuous
variables (age, BMI, WC, blood pressure) between
cases and controls were analyzed by Independent
samples t test. The frequencies of methylated
Pak J Med Sci
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and unmethylated ABO gene promoter among
AMI patients and normal healthy controls were
compared using Chi-Square test. In order to study
the association of methylation status of ABO gene
promoter, binary logistic regression was used.
A p value < 0.05 was considered statistically
significant.
RESULTS
Fig.1 shows the gel picture of a typical
methylation specific PCR (MSP). Being a sensitive
technique it enables the examination of all CpG
sites. Moreover, it permits simultaneous detection
of both methylated and unmethylated products in
a single DNA sample.13
The baseline demographic and clinical
characteristics of both AMI patients and normal
healthy subjects serving as controls have been
compared and indicate statistically significant
differences between the two groups in age and
waist circumference (p value < 0.001 and p
value = 0.005, respectively), while no significant
differences were observed with respect to gender,
BMI, systolic blood pressure and diastolic blood
pressure (Table-I). Frequency distribution of
methylated and unmethylated ABO gene promoter
in Pakistani AMI patients and normal healthy

Fig.1: Methylation specific PCR (MSP) amplified
products using methylated primer set marked as
M and unmethylated primer ser marked as U
for ABO gene promoter in AMI patients and
normal and normal healthy controls.
Lane 1= 100bp Marker, Lane 2-5= Normal healthy
control samples (band in only unmethylated), Lane 6-9=
AMI patients samples (bands in both unmethylated
and methylated), M = Methylated PCR product, U =
Unmethylated PCR product.
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Table-I: Baseline and clinical characteristics of normal
healthy controls and patients with acute myocardial
infarction (AMI) in a Pakistani population.
Characteristics

Normal healthy AMI patients
controls (n =39) (n =39) n (%)
n (%)

Gender
Males
Females

32(82.1)
7 (17.9)

33(84.6)
6 (15.4)

Mean ± SD

Mean ± SD

Age (years)
42.13 ± 7.68
BMI (kg/m2)
25.1 ± 3.8
WC (cm)
90.3 ± 8.7
SBP (mm of Hg)
119 ± 14
DBP (mm of Hg)
78 ± 7

53.87±8.87
25.8 ± 3.8
96.4 ± 9.8
120 ± 14
78 ± 12

Table-II. Frequency distribution of methylated
and unmethylated status of ABO gene
promoter in a Pakistani population.
Status of ABO gene promoter

p value*
Subjects

0.99

Cases (n=39)
Controls (n=39)

Unmethylated
(%)

Methylated
(%)

P value*

7 (17.9)
25 (64.1)

32 (82.1)
14 (35.9)

< 0.001

*p value was determined using chi-square test.
p value < 0.05 was considered as significant.
< 0.001
0.473
0.005
0.75
0.95

BMI: body mass index, WC: waist circumference,
SBP: systolic blood pressure,
DBP: diastolic blood pressure.
* p value represents the comparison of percentages in two
groups using chi-square, while means were compared
using Independent samples t test. A p value < 0.05 was
considered as significant.

controls has been shown Table-II. Significantly
higher proportion of DNA methylation has been
found in the ABO gene promoter of AMI patients
as compared to healthy controls (82.1% vs. 35.9%;
p value < 0.001). Binary logistic regression analysis
revealed an association of higher methylation
status of ABO gene promoter with AMI and the
odds of AMI were 6.27 folds higher in methylated
ABO gene promoter subjects compared to subjects
with unmethylated ABO gene promoter, when
adjusted for age and waist circumference [AOR
(95% CI) = 6.27 (1.76-22.3); p value 0.005, Table-III].
As epigenetic changes, in general, increase with
age,14 the regression model to study association
of promoter with AMI was adjusted for age.
Moreover, waist circumference has been reported
to be a better predictor of CAD compared to BMI
in Pakistani population,15 therefore, the logistic
regression model was also adjusted for waist
circumference. When the ABO gene promoter
was hypermethylated, the odds of having AMI
increased more than 6 folds in this population.

DISCUSSION
Coronary heart disease (CHD) is the major cause
of death in Pakistan.8 Another study from Pakistan
indicated that prevalence of CAD was more than
6% in people of the age greater than 30 years.16
Since non-O group individuals predominate in this
population, it is conceivable that the risk of CAD
would be high in this population. The underlying
mechanism of association of non-O blood group
antigens with CAD has not been defined clearly,
however there are reports which show that
non-O group subjects have 25% higher levels of
factor VIII-vWF complex compared to group O
individuals and vWF (von Willibrand factor) is
known to have a role in thrombosis by mediating
the adhesion of platelets to vascular wall and
promoting their aggregation, thereby increasing
the risk of CAD.17 Moreover, expression of ABO
gene locus is also associated with plasma levels of
lipids. For example, blood group A subjects have
been found to have higher levels of total cholesterol
and low-density lipoprotein cholesterol.18 Another
possible mechanism for the association of blood
groups A and non-O could be increased expression
of inflammatory molecules such as tumor necrosis
factor alpha which is known to mediate endothelial
cell activation by increasing the expression of
various adhesion molecules.17 All these reports
show the possible mechanism linking ABO gene
locus with the risk of CAD. However, most of these
lines of evidence deal with traditional risk factors
of CHD. Besides these traditional risk factors,
epigenetic factors could also be playing some role

Table-III: Association of ABO gene promoter’s methylation with the
risk of AMI in a Pakistani population using binary logistic regression.
Status of ABO gene promoter

Crude OR (95% CI)

Unmethylated
Methylated

p value

Adjusted OR (AOR)1 (95% CI)

1.0		 1.0
8.1 (2.86-23.26)
<0.001
6.27 (1.76-22.3)

Adjusted for age and waist circumference.

1
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for the high prevalence of this disease in Pakistan.
Epigenetic refers to changes in gene expression
without alteration in DNA sequence in response
to environmental factors such as smoking, diet and
lack of physical activity.19 DNA methylation on the
CpG islands in the gene promoter region is one of
the most studied epigenetic modifications.20 It has
been shown to regulate the expression of genes
associated with cardiovascular disease (CVD) risk
factors including atherosclerosis, inflammation,
hypertension and diabetes mellitus.21,22 Recent
studies have shown ABO gene locus as a
susceptibility locus for CAD, MI and other diseases,
and the environmental factors and epigenetic
signatures contribute in the process of development
of CAD.23 There is evidence of association of non-O
blood groups to the risk of developing CAD.2
However, in certain populations, there was no
significant association of non-O group with the risk
of CAD.24 This indicates that this association could
vary from one population to another.
There has been no report in the literature
describing the relationship of expression of ABO
gene promoter with the risk of CAD in South
Asian population. Kominato et al. had described
that hypermethylation of ABO gene promoter
caused silencing of the gene in stomach carcinoma
cell line.5 Later Bianco-Miotto et al., reported
that hypermethylation of ABO promoter was
associated with the loss of ABO allelic expression
in patients with leukemia.25 Therefore, the current
study is unique in reporting the association of
higher methylation of ABO gene promoter to
the risk of AMI in a Pakistani population. The
mechanism by which hypermethylation of ABO
gene promoter could be related to the risk of AMI
is unclear. However, it can be conjectured that
similar to the allelic loss observed in patients with
hematological malignancies,25 there could be a
loss of ABH antigens in patients with AMI with
associated complications such as thrombosis and
altered endothelial function.26 Duygu et al., have
reported association of DNA methylation with
arrhythmias and heart failure.27 Though they
have not described the mechanism involved, but
their findings do indicate a relationship of gene
silencing with heart disease.
Limitations of the study: Though the sample size
was modest, however, the study had adequate
power to investigate the relationship between
hypermethylation of promoter and risk of
AMI. Furthermore, the design of the study was
Pak J Med Sci
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cross sectional; therefore, it could only provide
information about association or relationship
between hypermethylation of ABO gene promoter
and risk of AMI. No cause-effect relationship could
be inferred from such a design. In order to obtain
information whether hypermethylation could
be the cause of AMI, some kind of longitudinal
studies would be required. Another limitation of
the current study is the lack of detailed information
about various drugs and medications used by the
patients and healthy controls because certain drugs
have been shown to alter the epigenetic profiling to
a favorable status.28 Thus, large studies involving
measurements at different time intervals along
with complete information about medicines used,
their diet, physical activity and comorbids would
be required to obtain some conclusive evidence
regarding the role of epigenetics in causing CAD in
Pakistani population.
CONCLUSION
There is an association between higher
methylation of ABO gene promoter and the risk
of AMI in a hospital-based Pakistani population.
Since the epigenetic changes are reversible, they
offer exciting opportunities for better treatment and
management of chronic diseases such as CVD.
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